ZVRA Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Revenue: $36.2 million, a 78% increase from $20.4 million in Q1 2025.

Breakdown:

$24.6 million from MyPlifer net sales in the U.S.

$10.2 million from global EAP reimbursements for aramcholamol.

$1.1 million in royalty revenue.

Net Income: $37.9 million ($0.62 per basic share; $0.60 per diluted share), compared to a net loss of $3.1 million in Q1 2025.

Adjusted net income (excluding one-time transactions): $11.5 million ($0.18 per diluted share).

Cash Position: $236.8 million, down $2.1 million from the previous quarter, primarily due to debt payoff.

Operating Expenses: $25.2 million, an increase of $2.4 million year-over-year.

2Strategic Updates and Business Highlights

Product Launch: MyPlifer is positioned as a foundational treatment for Niemann-Pick disease type C (NPC), with 170 prescription enrollment forms received since launch.

Global Access: 122 patients enrolled in the Global Expanded Access Program (EAP), with ongoing efforts to expand access in Europe.

Pipeline Development: Advancing ciliprole through a Phase III study for vascular Ehlers-Danlos syndrome (VEDS) with 62 patients enrolled in the DISCOVER trial.

Portfolio Optimization: Sold the FDX portfolio to CommAv Therapeutics for $50 million, enhancing focus on core assets and retiring debt.

3Forward Guidance and Outlook

The company aims to leverage its strong cash position and market presence to drive growth in rare disease therapeutics.

Continued focus on expanding patient access and accelerating clinical development for ciliprole.

Anticipation of regulatory decisions regarding aramcholamol in Europe, which could further enhance market opportunities.

4Challenges and Points of Concern

Channel Inventory: Fell below the targeted range due to one less shipment week, which may impact future sales.

Patient Identification: While there is a strong focus on using AI and genetic testing for patient identification, the conversion rate from identified patients to treatment remains a concern.

Market Competition: Ongoing competitive pressures in the rare disease market, particularly with the introduction of new therapies.

5Notable Q&A Insights

Physician Adoption: The addition of MyPlifer to NPC clinical practice guidelines is expected to enhance physician adoption and treatment consistency.

Patient Identification: The company is tracking metrics related to newly diagnosed patients and prescriber engagement, indicating a positive trend in awareness and diagnosis.

EAP Revenue Growth: France has been a significant contributor to EAP revenue, but the company is expanding access in other European markets.

Reimbursement Pathways: 69% of covered lives currently have access to MyPlifer, with ongoing efforts to improve this figure through payer education and support services. Overall, Zevra Therapeutics is demonstrating strong financial performance and strategic positioning in the rare disease market, with a focus on expanding access and driving growth, despite facing some operational challenges and competitive pressures.